RUO - FGFR4 / 5q11.2

ruo-fgfr4-5q112
It is well documented that dysregulation of FGF-FGFR signaling via amplification, point mutation or translocations may have an important role in tumor development and progression. Alterations in FGFRs are associated with a number of human cancers, including lung, myeloma, breast, gastric, colon, bladder, pancreatic, and hepatocellular carcinomas. A growing body of preclinical data demonstrates that inhibition of FGFR signaling can result in antiproliferative and/or pro-apoptic effects, thus confirming the validity of the FGFR / FGFR axis as a potential therapeutic target. The FGFR4 (5q35) FISH probe is optimized to detect copy numbers of the FGFR4 gene region at region 5q35. The 5q11.2 probe is included to facilitate chromosome identification.

References:
Brooks et al, Clin Cancer Res. 2012; 18:1855.
Dutt et al, PLoS ONE 6: e2035.1.
Kunii et al, Cancer Res. 2008; 68:2340-8.
Liang et al, Clin Cancer Res. 2013;19: 2572.
Liao et al, Cancer Res. 2013; 73:5195-205.
Weiss et al, Sci Transl Med. 2010; 2:62ra93.
  • KI-10756
    FGFR4 (5q35) / 5q11.2

製品仕様書

製品仕様書

KI-10756
Research
Research Use Only
10 test
Dual Color > Red, Green
Tissue
Amplification
Gene Region-Specific
Fluorescent
Ready-to-Use
Manual Reagent

カタログ・取扱説明書など

カタログ・取扱説明書など

関連資料

関連資料

It is well documented that dysregulation of FGF-FGFR signaling via amplification, point mutation or translocations may have an important role in tumor development and progression. Alterations in FGFRs are associated with a number of human cancers, including lung, myeloma, breast, gastric, colon, bladder, pancreatic, and hepatocellular carcinomas. A growing body of preclinical data demonstrates that inhibition of FGFR signaling can result in antiproliferative and/or pro-apoptic effects, thus confirming the validity of the FGFR / FGFR axis as a potential therapeutic target. The FGFR4 (5q35) FISH probe is optimized to detect copy numbers of the FGFR4 gene region at region 5q35. The 5q11.2 probe is included to facilitate chromosome identification.

References:
Brooks et al, Clin Cancer Res. 2012; 18:1855.
Dutt et al, PLoS ONE 6: e2035.1.
Kunii et al, Cancer Res. 2008; 68:2340-8.
Liang et al, Clin Cancer Res. 2013;19: 2572.
Liao et al, Cancer Res. 2013; 73:5195-205.
Weiss et al, Sci Transl Med. 2010; 2:62ra93.

Recently Viewed